Orforglipron vs Tirzepatide
Which Is Right for You? Complete Comparison (2026)
Orforglipron vs Tirzepatide comparison — Eli Lilly oral GLP-1 pill vs dual GLP-1/GIP weekly injection, weight loss efficacy.
Orforglipron vs Tirzepatide: At a Glance
- ✓Non-peptide oral GLP-1 receptor agonist (small molecule)
- ✓Does not require fasting before administration
- ✓~14.7% weight loss at 36 weeks in phase 2
- ✓Once-daily oral dosing — no injection needed
- ✓Phase 3 trials ongoing — Eli Lilly
- ✓Dual GIP + GLP-1 receptor agonist — first in class
- ✓GIP agonism enhances insulin sensitivity in adipose tissue
- ✓~21% mean weight loss at 72 weeks (SURMOUNT-1, 15 mg)
- ✓GIP may moderate GI side effects vs GLP-1-only drugs
- ✓Half-life ~5 days — once-weekly injection
Detailed Comparison
| Feature | Orforglipron | Tirzepatide |
|---|---|---|
| Mechanism | Oral non-peptide GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonistBest |
| Dosing | 12-36-45 mg orally daily (phase 2 doses) | 2.5-15 mg SC weekly |
| Administration | Oral | Subcutaneous injection weekly |
| Half-life | ~28-47 hours | ~5 days |
| FDA Status | Not FDA-approved — phase 3 clinical trials | FDA-approved: Mounjaro (T2D), Zepbound (obesity) |
| Key Trial | Wharton S et al. NEJM 2023 — phase 2 obesity trial | Jastreboff AM et al. NEJM 2022 (SURMOUNT-1) — 20.9% weight loss |
| Side Effects | Nausea, vomiting, diarrhea (dose-dependent) | Nausea (31%), vomiting, diarrhea, constipation |
Which Should You Choose?
Orforglipron (oral non-peptide glp-1 receptor agonist) and Tirzepatide (dual gip/glp-1 receptor agonist) serve different clinical roles despite both being in the Oral GLP-1 agonist space. Orforglipron small molecule oral glp-1 receptor agonist that does not require fasting for absorption — unlike oral semaglutide. Tirzepatide first-in-class dual gip and glp-1 receptor agonist that activates two incretin pathways for enhanced weight loss and glycemic control vs single agonists.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Orforglipron and Tirzepatide
Choosing between Orforglipron and Tirzepatide depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Orforglipron and Tirzepatide is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Orforglipron vs Tirzepatide: Frequently Asked Questions
Orforglipron is an oral non-peptide glp-1 receptor agonist while Tirzepatide is a dual gip/glp-1 receptor agonist. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Orforglipron works as a oral non-peptide glp-1 receptor agonist (12-36-45 mg orally daily (phase 2 doses)), while Tirzepatide is a dual gip/glp-1 receptor agonist (2.5-15 mg SC weekly). They have different half-lives (~28-47 hours vs ~5 days), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Orforglipron or Tirzepatide in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.